JP2025511404A - オシメルチニブを製造するための改善されたプロセス - Google Patents

オシメルチニブを製造するための改善されたプロセス Download PDF

Info

Publication number
JP2025511404A
JP2025511404A JP2024559037A JP2024559037A JP2025511404A JP 2025511404 A JP2025511404 A JP 2025511404A JP 2024559037 A JP2024559037 A JP 2024559037A JP 2024559037 A JP2024559037 A JP 2024559037A JP 2025511404 A JP2025511404 A JP 2025511404A
Authority
JP
Japan
Prior art keywords
formula
compound
salt
reaction
carried out
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024559037A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025511404A5 (https=
Inventor
キーロン マレン,アレクサンダー
ポッツォーリ,アレッサンドロ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2025511404A publication Critical patent/JP2025511404A/ja
Publication of JP2025511404A5 publication Critical patent/JP2025511404A5/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/02Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Epidemiology (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
JP2024559037A 2022-04-07 2023-04-06 オシメルチニブを製造するための改善されたプロセス Pending JP2025511404A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263362622P 2022-04-07 2022-04-07
US63/362,622 2022-04-07
PCT/EP2023/059132 WO2023194531A1 (en) 2022-04-07 2023-04-06 Improved process for the manufacture of osimertinib

Publications (2)

Publication Number Publication Date
JP2025511404A true JP2025511404A (ja) 2025-04-15
JP2025511404A5 JP2025511404A5 (https=) 2026-04-14

Family

ID=86142780

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024559037A Pending JP2025511404A (ja) 2022-04-07 2023-04-06 オシメルチニブを製造するための改善されたプロセス

Country Status (14)

Country Link
US (1) US20250250255A1 (https=)
EP (1) EP4504718A1 (https=)
JP (1) JP2025511404A (https=)
KR (1) KR20250002363A (https=)
CN (1) CN119317624A (https=)
AR (1) AR128999A1 (https=)
AU (1) AU2023250220A1 (https=)
CA (1) CA3255378A1 (https=)
CO (1) CO2024015096A2 (https=)
IL (1) IL316018A (https=)
MX (1) MX2024012370A (https=)
TW (1) TW202404955A (https=)
WO (1) WO2023194531A1 (https=)
ZA (1) ZA202408113B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120717920A (zh) * 2025-08-18 2025-09-30 爱斯特(成都)生物制药股份有限公司 一种微通道连续合成3-硝基-4-氟苯腈的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4119551A1 (en) 2011-07-27 2023-01-18 Astrazeneca AB 2-(2,4,5-substituted-anilino)pyrimidine compounds
CN106883216B (zh) * 2017-04-06 2020-03-13 张家港威胜生物医药有限公司 一种奥希替尼的制备方法
IN201741031902A (https=) * 2017-09-08 2019-03-15 Msn Laboratories Private Ltd
CN109134435B (zh) 2018-10-29 2023-01-03 湖南大学 一种奥希替尼azd9291的合成方法

Also Published As

Publication number Publication date
CN119317624A (zh) 2025-01-14
AR128999A1 (es) 2024-07-03
ZA202408113B (en) 2025-07-30
KR20250002363A (ko) 2025-01-07
TW202404955A (zh) 2024-02-01
WO2023194531A1 (en) 2023-10-12
MX2024012370A (es) 2024-11-08
AU2023250220A1 (en) 2024-11-07
IL316018A (en) 2024-11-01
CO2024015096A2 (es) 2024-11-28
EP4504718A1 (en) 2025-02-12
CA3255378A1 (en) 2023-10-12
US20250250255A1 (en) 2025-08-07

Similar Documents

Publication Publication Date Title
JP7100125B2 (ja) リボシクリブおよびその塩の改善された調製のためのプロセス
US9233955B2 (en) Process for the preparation of azilsartan medoxomil
KR102625774B1 (ko) 오메캄티브 메카빌의 합성
CN111333633A (zh) 一种瑞卢戈利的中间体化合物及其制备方法和用途
CN102985416B (zh) 制备凝血酶特异性抑制剂的方法
JP6175122B2 (ja) 2−アミノ−n−(2,2,2−トリフルオロエチル)アセトアミドの調製方法
CN107922352B (zh) 制备蛋白质脱乙酰酶抑制剂的方法
JP2025511404A (ja) オシメルチニブを製造するための改善されたプロセス
CN115073490A (zh) 一种瑞卢戈利及其中间体的制备方法
WO2001025185A1 (en) Process for the preparation of a piperazine derivative
CN116535384A (zh) 替卡格雷中间体的制备方法
CN115073491A (zh) 一种瑞卢戈利中间体、其制备方法及其应用
CN115477653B (zh) 一种曲拉西利关键中间体及曲拉西利的制备方法
JP2020070296A (ja) リナグリプチンの製造法
JP2015038053A (ja) 4−(2−メチル−1−イミダゾリル)−2,2−フェニルブタンアミドの製造方法
CN103130700A (zh) 一种阿折地平中间体的制备方法
US20150322050A1 (en) Efficient Process for the Preparation of Lapatinib and Salts Thereof by Means of New Intermediates
CN103052638B (zh) 制备地来西坦的方法
CN113024521B (zh) 一种制备恩曲替尼的方法
WO2013001511A1 (en) Novel salt intermediates for the synthesis of bazedoxifene acetate and process thereof
US9040697B2 (en) Process for the production of moxonidine
JP2001526253A (ja) イソプロピル−メチル−[2−(3−n−プロポキシフェノキシ)エチル]アミンの製造方法
WO2024137495A1 (en) Fostemsavir intermediates and process for the preparation thereof
JP6336166B2 (ja) イミダフェナシンの新規中間体、その製造方法及びそれを用いたイミダフェナシンの製造方法
JP5034277B2 (ja) 3−(n−アシルアミノ)−3−(4−テトラヒドロピラニル)−2−オキソプロパン酸エステル及び3−(n−アシルアミノ)−3−(4−テトラヒドロピラニル)−2−オキソプロパノヒドラジドの製造方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260406

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260406